1. (ACNP—FDA) American College of Neuropsychopharmacology—Food and Drug Administration Task Force (1973). Neurological syndromes associated with antipsychotic drug use. Arch. Gen. Psychiat. 28: 463–467.
2. Allen, R.E., and Stimmel, G.L. (1977). Neuroleptic dosage, duration, and tardive dyskinesia. Dis. Nerv. Syst. 38: 385–387.
3. Ayd, F.J., Jr. (1976a). On the reversibility of tardive dyskinesia. Int. Drug Ther. Newsletter. 11: 9: 35–36.
4. Ayd, F.J., Jr. (1976b). Sodium valproate therapy for tardive dyskinesia. Int. Drug Ther. Newsletter. 12: 8, 9: 29–34.
5. Ayd, F J., Jr. (1972). Treatment of persistent dyskinesia. Int. Drug Ther. Newsletter. 7: 3: 9–11.